DrugBiological
Apricoxib clinical trials
Also written TG01.
Keep track of what changes. Save the apricoxib studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
8 studies that test it; most in 2008 (4)
| Year | Studies |
|---|---|
| 2007 | 1 |
| 2008 | 4 |
| 2011 | 1 |
| 2012 | 1 |
| 2023 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 5 · Other 3
Tragara Pharmaceuticals, Inc. (4) · Targovax ASA (1) · University of Maryland, Baltimore (1) · Oslo University Hospital (1) · Jonsson Comprehensive Cancer Center (1)
Often tested with
Tested in the same studies.
Related medicines
As reviewed, each with the page that says it.
- One of Cyclooxygenase 2 Inhibitors source
- One of Cyclooxygenase Inhibitors source
Studies
Open first, then newest update. How each study uses apricoxib is read from its arms, and is right about nine times in ten.
Testing it · 8
- The TG01 Study With TG01/QS-21 Vaccine in Patients With High-risk Smouldering Multiple Myeloma and Multiple MyelomaRecruitingPhase 1/2Oslo University HospitalNCT05841550Written as TG01
- Evaluation of Apricoxib (Selective Cyclooxygenase 2 Inhibition) in Modulating T Regulatory Cells of Patients With Early Stage Non-small Cell Lung CancerTerminatedNot applicableJonsson Comprehensive Cancer CenterNCT01532362Written as Apricoxib
- Antigen-specific Cancer Immunotherapy (TG01) and Gemcitabine as Adjuvant Therapy in Resected Pancreatic CancerCompletedPhase 1/2Targovax ASANCT02261714Written as TG01
- 0822GCC: Phase 2 Study of Efficacy and Safety of Apricoxib/Placebo With Docetaxel or Pemetrexed in Non-Small Cell Lung CancerCompletedPhase 2University of Maryland, BaltimoreNCT00771953Written as apricoxib
- APRiCOT-P: Study of Apricoxib With Gemcitabine and Erlotinib to Treat Advanced Pancreatic CancerCompletedPhase 2Tragara Pharmaceuticals, Inc.NCT00709826Written as apricoxib
- APRiCOT-L: Study to Evaluate Efficacy and Safety of Apricoxib With Erlotinib in Patients With Non-small Cell Lung CancerCompletedPhase 2Tragara Pharmaceuticals, Inc.NCT00652340Written as apricoxib/erlotinib
- APRiCOT-B: Study to Evaluate Apricoxib in Combination With Lapatinib and Capecitabine in the Treatment of HER2/Neu+ Breast Cancer (TP2001-202)TerminatedPhase 2Tragara Pharmaceuticals, Inc.NCT00657137Written as apricoxib + lapatinib + capecitabine
- Phase 1 Study of TG01 and Erlotinib in Non-small Cell Lung Cancer (NCSLC) PatientsCompletedPhase 1Tragara Pharmaceuticals, Inc.NCT00569114Written as TG01
Given in every arm · 1 — apricoxib is usual care beside what is tested
Codes
What other systems call apricoxib · ClinicalTrials.gg INT004982
- MeSH (NLM) C514354apricoxibOne source NLM
- UNII (FDA) 5X5HB3VZ3ZAPRICOXIBConfirmed FDA, NLM, Wikidata
- Wikidata Q18209480apricoxibConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C74021ApricoxibOne source FDA
- DrugBank DB12378One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C514354 | apricoxib | One source NLM |
| UNII (FDA) | 5X5HB3VZ3Z | APRICOXIB | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q18209480 | apricoxib | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C74021 | Apricoxib | One source FDA |
| DrugBank | DB12378 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.